Palvella Therapeutics (NASDAQ:PVLA – Get Free Report)‘s stock had its “overweight” rating reaffirmed by equities researchers at Stephens in a report released on Thursday,Benzinga reports. They currently have a $220.00 price target on the stock. Stephens’ price target would indicate a potential upside of 90.57% from the stock’s previous close.
Several other equities analysts also recently issued reports on PVLA. Truist Financial set a $210.00 price objective on shares of Palvella Therapeutics in a research note on Tuesday, February 24th. Chardan Capital reiterated a “buy” rating and set a $240.00 target price on shares of Palvella Therapeutics in a research note on Thursday. Wall Street Zen downgraded shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. BTIG Research increased their target price on shares of Palvella Therapeutics from $192.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Finally, TD Cowen reiterated a “buy” rating on shares of Palvella Therapeutics in a research note on Monday, February 2nd. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $199.53.
View Our Latest Stock Analysis on PVLA
Palvella Therapeutics Trading Down 0.0%
Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($1.20) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.30). On average, sell-side analysts forecast that Palvella Therapeutics will post -5.43 earnings per share for the current year.
Insider Transactions at Palvella Therapeutics
In other Palvella Therapeutics news, Director George M. Jenkins bought 4,000 shares of the firm’s stock in a transaction dated Friday, February 27th. The stock was acquired at an average price of $125.00 per share, for a total transaction of $500,000.00. Following the completion of the purchase, the director owned 187,171 shares of the company’s stock, valued at approximately $23,396,375. This represents a 2.18% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $117.99, for a total transaction of $507,592.98. The SEC filing for this sale provides additional information. Insiders own 20.50% of the company’s stock.
Institutional Investors Weigh In On Palvella Therapeutics
A number of hedge funds have recently added to or reduced their stakes in PVLA. Millennium Management LLC acquired a new stake in Palvella Therapeutics in the first quarter valued at about $7,553,000. Goldman Sachs Group Inc. acquired a new stake in Palvella Therapeutics in the first quarter valued at about $533,000. Geode Capital Management LLC lifted its position in Palvella Therapeutics by 84.7% in the second quarter. Geode Capital Management LLC now owns 173,986 shares of the company’s stock valued at $3,923,000 after purchasing an additional 79,787 shares during the period. JPMorgan Chase & Co. lifted its position in Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after purchasing an additional 3,242 shares during the period. Finally, Rhumbline Advisers acquired a new stake in Palvella Therapeutics in the second quarter valued at about $224,000. Institutional investors and hedge funds own 40.11% of the company’s stock.
Palvella Therapeutics Company Profile
Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.
Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.
Featured Stories
- Five stocks we like better than Palvella Therapeutics
- The Silver Lining of Last Week’s Hims & Hers Earnings Miss
- 2 Software Stocks Turning AI Fears Into Fundamental Gains
- The Token Takeover: SEC Triggers Market Quake
- Target Shows Strengths, But Analysts Want to See More
Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
